Présentation de l'entreprise
ADMA Biologics, Inc. operates as a specialized biopharmaceutical entity dedicated to the development, manufacturing, and marketing of specialty plasma-derived biologics designed to treat immune deficiencies and infectious diseases within both the United States and international markets. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, which implies a focus on innovative research and high-value therapeutic products rather than traditional commodity manufacturing. With a market capitalization of $2.34 billion and annual revenue reaching $510.17 million, ADMA maintains a substantial presence with an employee base of 640 individuals. These valuation and revenue figures indicate that the company occupies a significant position in the niche market for plasma-derived biologics, suggesting it has established a scalable business model capable of generating substantial top-line growth while managing complex regulatory and operational environments.
Santé financière
The company reported a trailing twelve-month revenue of $510.17 million and a corresponding net income of $146.93 million, supported by an EBITDA of $199.54 million. The substantial gap between the $510.17 million in revenue and the $146.93 million in net income reveals a gross margin structure of 57.4%, yet the operating margin stands at a negative -123.4%, indicating significant operating expenses that currently outweigh operating revenue in the standard calculation, while the reported profit margin of 28.8% suggests specific accounting treatments or non-operating income sources are influencing the bottom line. Despite the reported free cash flow of -$18,154,876, the balance sheet lists a cash position of $55.92 billion against a debt load of $97.67 billion. The current ratio of 6.71 demonstrates robust short-term liquidity, as the company holds significantly more current assets than current liabilities to cover its immediate obligations. Regarding capital structure, the debt-to-equity ratio is listed as 110.67, which, when paired with the massive cash reserve, presents a complex leverage profile where the reported cash far exceeds the reported debt, though the ratios suggest high financial magnification. Management effectiveness is further illuminated by a return on equity of 35.6% and a return on assets of 21.5%, metrics that indicate highly efficient utilization of shareholder capital and asset base to generate returns.
Évaluation de la valorisation
Valuation metrics for ADMA show a trailing P/E ratio of 16.38 compared to a forward P/E of 7.12. The discrepancy between these two figures implies that the market expects earnings growth in the future that would allow the forward valuation to be significantly lower than the historical average, or it reflects a one-time event impacting the trailing earnings. The price-to-book ratio stands at 4.90, which indicates that the market values the company at nearly five times its book value, suggesting a high market premium attributed to the intangible assets and growth potential of its biologic portfolio. Alternative valuation indicators such as the price-to-sales ratio of 4.59 and an EV/EBITDA of 220.95 suggest that the stock is priced heavily relative to its sales and earnings before interest, taxes, depreciation, and amortization, reflecting investor confidence in future expansion. In terms of trading range, the 52-week high is recorded at $25.67 while the 52-week low is $7.21, meaning the current price sits within this wide band but the specific current price is not provided in the available facts to calculate a precise percentage deviation. The beta of 0.82 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations than large-cap benchmarks.
Growth & Income
Revenue growth for the company is recorded at 15.9% year-over-year, while earnings growth is listed as N/A. The absence of a specific earnings growth rate relative to the robust revenue growth implies that the bottom line expansion is either not yet tracked in the same timeframe or is driven by one-time factors rather than recurring operational scaling. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all of its generated earnings into research, development, and manufacturing capacity rather than distributing cash to shareholders. This strategy aligns with the capital-intensive nature of the biotechnology industry, where funds are prioritized for expanding the plasma collection network and developing new biologics. Overall, the growth and income profile is defined by strong top-line expansion and a complete reinvestment of profits, with no current reliance on dividend income for investors.